Screener Summaries Updates Institutions Sign In More Updates › Other Events › NGNE Other Events · Jun 8, 2026
Neurogene Inc. announced the completion of dosing in its Embolden TM registrational trial of NGN-401 for the treatment… NGNE Neurogene Inc.
Neurogene Inc. announced the completion of dosing in its Embolden TM registrational trial of NGN-401 for the treatment of Rett syndrome on June 8, 2026. The company also updated its corporate presentation on its website.
More from Neurogene Inc. Neurogene Inc. reported second quarter 2026 financial results on August 11, 2026, announcing a net loss of $34.5… Aug 11, 2026 Neurogene Inc. entered into an underwriting agreement on June 30, 2026, to issue and sell 3,500,000 shares of common… Jul 1, 2026 Neurogene Inc. announced on June 29, 2026, positive, updated clinical data from its Phase 1/2 trial evaluating NGN-401… Jun 29, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
